Fundraising Fox
Sonalasense
Berkeley, US · Founded 2019 · New York corporation · 1 known investors
Find your way into Sonalasense
Sign up to find every way you can get introduced to Sonalasense
- Your email: who you already know at Sonalasense, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Sonalasense team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
SonALAsense develops Sonodynamic Therapy (SDT), a non-invasive drug-device cancer treatment combining its SONALA-001 drug with an ultrasound device to treat deadly cancers such as High-Grade Gliomas and DIPG. The company is running Phase 0/1 and Phase 1/2 clinical trials and targets patients with brain tumors that typically require surgery.
Founders & leadership
Investors · 1
Reported raises · per SEC filings
Form D private placements$34.8M disclosed across 4 rounds · 2019–2023
▶$9.8MraisedNov 2023 · 30 investors · BiotechnologyRule 506(b)
- MARK P. DE SOUZAExecutive Officer, Director
- STUART MARCUSExecutive Officer, Director
- VINCENT SAIDirector
- Offering amount
- $15M
- Amount sold
- $9.8M
- First sale
- Feb 2023
- Incorporated
- Corporation, New York, 2019
- Federal exemptions
- 06b
▶$20.1MraisedJan 2022 · 30 investors · BiotechnologyRule 506(b)
- Stuart MarcusExecutive Officer, Director
- Mark P. de SouzaExecutive Officer, Director
- Offering amount
- $30.1M
- Amount sold
- $20.1M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$3.9MraisedFeb 2021 · 26 investors · BiotechnologyRule 506(b)
- Stuart MarcusExecutive Officer, Director
- Mark P. de SouzaExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $3.9M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1000KraisedSep 2020 · 13 investors · BiotechnologyRule 506(b)
- Stuart MarcusExecutive Officer, Director
- Mark P. de SouzaExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1000K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Sonalasense.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $694.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Sonalasense do?
- SonALAsense develops Sonodynamic Therapy (SDT), a non-invasive drug-device cancer treatment combining its SONALA-001 drug with an ultrasound device to treat deadly cancers such as High-Grade Gliomas and DIPG. The company is running Phase 0/1 and Phase 1/2 clinical trials and targets patients with brain tumors that typically require surgery.
- Who are Sonalasense's investors?
- Sonalasense's investors include Keiretsu Forum.
- How much funding has Sonalasense raised?
- Sonalasense has disclosed $34.8M raised across 4 rounds.
- Where is Sonalasense headquartered?
- Sonalasense is headquartered in Berkeley, US.